Search results
Added:
6 months ago
Added:
2 years ago
ESC 2023 — Dr Tobias Reichlin (Inselspital, University of Bern, CH) joins us on-site at ESC 2023 to discuss the findings of the COMPARE-CRYO Trial (NCT04704986).
The COMPARE-CRYO trial (Insel Gruppe AG, University Hospital Bern) aimed to compare the safety and efficacy of the PolarX Cryoballoon (Boston Scientific) with the Arctic Front Cryoballoon (Medtronic) in patients with symptomatic…
View more
Added:
2 weeks ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional…
View more
Added:
2 weeks ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Added:
1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,…
View more
Added:
6 days ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Added:
6 days ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients…
View more
Added:
5 days ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)…
View more
Added:
5 days ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more